Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2017 Financial Results

Cidara Therapeutics (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months and full year ended December 31, 2017, and provided an update on its corporate activities and product pipeline.

As quoted in the press release:

“I am pleased to share Cidara’s progress during the fourth quarter of 2017 and subsequently.  Our accomplishments included the completion of enrollment in our STRIVE Phase 2 clinical trial of rezafungin in candidemia and invasive candidiasis, a successful financing and continued outreach to the medical and scientific communities,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “In the near term we are focused on the topline data read-out from the STRIVE study, which we expect by the end of the first quarter.”

Click here to read the full press release.